ImmunID – a biotech company founded in Grenoble in 2005 – has developed a multi-pronged approach to immune system testing, which goes beyond simple phenotyping.
|
Minatec Video Mini Player
|
ImmunID has developed a range of specialized biological testing kits and services based on technology backed up by CEA and INSERM patents. ImmunID has been awarded the world’s first contract for Divpenia®, a new immune system marker that enables the routine analysis of different types of T and B lymphocytes.
ImmunID’s tests are especially effective at assessing a patient’s immune defenses before, during, and after treatments for major diseases like cancer, AIDS, and hepatitis C. They can also help pharmaceutical companies to better target new drug trials by allowing for more specific selection and monitoring of patient groups.
ImmunID is a member of the Lyonbiopôle cluster and the CLARA cancer research cluster, and counts some 20 employees. Its technology is used by Roche Diagnostics, the global leader in molecular biology diagnostics, to enhance their quantitative PCR machines. ImmunID is currently working with the Léon-Bérard Centre and the Hospices Civils de Lyon on studies testing several hundreds of patients.
Learn more at: www.immunid.com
